Linden Advisors’s Nuvation Bio NUVB Stock Holding History

Linden Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-150,000	Closed	-$1.75M	–	737
2020 Q4	$1.75M	Buy	+150,000	New	+$1.56M	0.01%	334

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Linden Advisors's NUVB Position: Q1 2021 in Review

Linden Advisors sold out of Nuvation Bio (NUVB) in Q1 2021, closing a stake of 150,000 shares — an estimated $1.75M sold.

Linden Advisors first reported a position in NUVB in Q4 2020 and held it in 1 quarter. The position peaked at $1.75M in Q4 2020. 73 funds tracked by Wall St. Rank hold NUVB as of Q1 2021.

Linden Advisors reported no remaining Nuvation Bio position as of Q1 2021 after selling out during the quarter.
Linden Advisors sold 150,000 Nuvation Bio shares in Q1 2021, an estimated $1.75M.
Linden Advisors first reported a position in Nuvation Bio in Q4 2020 and held it in 1 quarter.
Linden Advisors's Nuvation Bio position peaked at $1.75M in Q4 2020.
73 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2021.

Based on Linden Advisors's 13F filing for Q1 2021, filed 17 May 2021.